Enrolled patients are then stratified into six independent cohorts based on the status of gene mutations and PD-L1 status in tumor tissues, that is, 1EGFR 19del group, 2EGFR 21 L858R group, 3EGFR rare mutation group, 4Other driver mutation group, 5Drive mutation-negative group with PD-L1≥1%, 6Drive mutation-negative group with PD-L1<1%. Here, CD274 is linked to neoplasm.